Targeted Genetics Sells AAV, Manufacturing Tech to Genzyme for $7M | GenomeWeb

Just days after it was poised to run out of cash, Targeted Genetics last week announced that it has sold its manufacturing and adeno-associated viral vector technologies, among other assets, to Genzyme for up to $7 million.

The transaction, which will enable the company to continue operations through 2010, will transfer Targeted Genetics’ patents, manufacturing-related equipment, and licenses to use certain technology and materials necessary for manufacturing AAV vectors to Genzyme, according to the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.